Please login to the form below

Not currently logged in
Email:
Password:

Former GSK exec joins PureTech Health

Dr Atul Pande becomes chief medical officer

PureTech Health Dr Atul PandeBoston, US-based PureTech Health has appointed Dr Atul Pande as its new chief medical officer, responsible for the firm's pipeline in immune, nervous and gastro-intestinal systems.

Dr Pande was formerly senior vice president and head of neuroscience at GlaxoSmithKline, where he also served as a senior advisor in its R&D division.

Prior to this, he was chief medical officer at Cenerx Biopharma and brings further R&D leadership experience from Pfizer, where he served as vice president for neurosciences.

Dr Pande currently serves on the board of directors for Karuna Pharmaceuticals - part of PureTech Health - as well as Axovant Sciences, Autifony Therapeutics, and Cennerv Pharma's scientific advisory board.

Daphne Zohar, chief executive officer of PureTech Health, said: “We are excited to work more closely with Atul and to have access to his drug development expertise across PureTech Health's pipeline.

“Atul is a seasoned drug development veteran who will help to shepherd our advancing pipeline through mid- and late-stage clinical trials while ensuring that synergies are leveraged across our platforms.”

27th February 2017

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...
Practical advice for Early Scientific Advice (ESA) in HTA submissions
A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence...